Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Revenue: 2017-2025

Historic Revenue for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $27.5 million.

  • UroGen Pharma's Revenue rose 9.04% to $27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 8.00%. This contributed to the annual value of $90.4 million for FY2024, which is 9.29% up from last year.
  • Latest data reveals that UroGen Pharma reported Revenue of $27.5 million as of Q3 2025, which was up 13.49% from $24.2 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Revenue ranged from a high of $27.5 million in Q3 2025 and a low of $7.5 million during Q1 2021.
  • Its 3-year average for Revenue is $22.3 million, with a median of $21.8 million in 2024.
  • Data for UroGen Pharma's Revenue shows a peak YoY soared of 227.97% (in 2021) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Revenue (Quarterly) stood at $16.2 million in 2021, then grew by 11.86% to $18.1 million in 2022, then spiked by 30.06% to $23.5 million in 2023, then rose by 4.40% to $24.6 million in 2024, then grew by 9.04% to $27.5 million in 2025.
  • Its Revenue stands at $27.5 million for Q3 2025, versus $24.2 million for Q2 2025 and $20.3 million for Q1 2025.